The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 07, 2020

Filed:

Mar. 06, 2015
Applicant:

Welson Pharmaceuticals, Inc., Beijing, CN;

Inventor:

Le Sun, Beijing, CN;

Assignee:

WELSON PHARMACEUTICALS, INC., Haidian District Beijing, CN;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/28 (2006.01); C12N 15/63 (2006.01); A61P 35/00 (2006.01); A61P 37/02 (2006.01); C07K 16/22 (2006.01); A61P 31/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/28 (2013.01); A61P 31/00 (2018.01); A61P 35/00 (2018.01); A61P 37/02 (2018.01); C07K 16/22 (2013.01); C07K 16/2863 (2013.01); C12N 15/63 (2013.01); C07K 2317/24 (2013.01); C07K 2317/515 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01);
Abstract

Disclosed herein are humanized anti-Epidermal Growth Factor (EGF) Receptor antibodies which can inhibit the proliferation of cells expressing the EGF receptor. Humanized anti-EGFR antibodies are capable of binding to the surface of cells and killing the EGF receptor overexpression cells. The invention presents the humanized anti-EGFR antibodies which bind to different epitope and inhibit the tumor formation in a different way than Erbitux. Most importantly, once bound to the surface EGFR, these new anti-EGFR antibodies will internalize rather quickly, which made them ideal candidate for antibody drug conjugation and other biotherapy. The invention also features method of humanization which leads to 90% of the amino acid sequences are human sequence, and significantly reduce the risk of human anti-mouse immunogenicity. The present invention also demonstrated that the humanized anti-EGFR antibodies have the affinity to EGFR in the range of 2.3 nM, which is very similar to the mouse anti-EGFR monoclonal antibody LA22.


Find Patent Forward Citations

Loading…